Actively Recruiting
Investigating BG-85738 Alone or with Other Antitumor Agents for Advanced or Metastatic Solid Tumors with RAS Mutations
Led by BeOne Medicines · Updated on 2026-10-23
100
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates BG-85738, a new experimental drug, in adults with advanced or metastatic solid tumors that have mutations in the RAS gene. It aims to evaluate the safety and effects of BG-85738 alone and in combination with other anticancer agents in patients whose cancer involves uncontrolled growth due to hyperactive RAS proteins. The study is conducted in two parts dose escalation to identify safe dosage levels, and dose expansion to study the drugs effects in more patients. Participants receive BG-85738 orally either by itself or combined with intravenous drugs tislelizumab or cetuximab. The dose escalation part tests ascending doses to find recommended levels without serious side effects. The dose expansion part treats participants with selected tumor types using the doses identified earlier, either as monotherapy or in combination with the other agents. The study involves multiple centers worldwide. Participants will visit clinics regularly over approximately 13 to 24 months for treatments and health monitoring. Assessments include blood tests, tumor imaging, and safety evaluations to track adverse events and drug effects. Researchers will measure outcomes such as response rates, progression-free survival, and drug levels over time. Safety is monitored up to 30 days after treatment ends, with ongoing follow-up to assess treatment impact and tolerability.
CONDITIONS
Brief Title
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here